Atlas Trials

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Clinical trial NCT04065087 · WITHDRAWN

Trial details

NCT number
NCT04065087
Sponsor
Genexine, Inc.
Status
WITHDRAWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Newly Diagnosed Glioblastoma
Start date
2019-08-22
Primary completion
2022-05-27
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.